Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...
T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...
Abstract and Introduction Risk Factors for HCC in the Absence of HBV or HCV Infection Prevention of Nonviral Liver Disease-related HCC References The mechanisms by which alcohol contributes to HCC ...
A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the ...
Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...
Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors. Like many rare ...
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback